Journal
FUTURE ONCOLOGY
Volume 11, Issue 8, Pages 1169-1179Publisher
FUTURE MEDICINE LTD
DOI: 10.2217/fon.14.274
Keywords
antiangiogenic; kidney; pazopanib; renal cancer; treatment; tyrosine kinase inhibitor
Categories
Funding
- GlaxoSmithKline
- Roche
- Cancer Research UK [11562] Funding Source: researchfish
- National Institute for Health Research [CL-2012-14-002] Funding Source: researchfish
Ask authors/readers for more resources
The incidence and mortality from renal cell cancer (RCC) is increasing. RCC tumors are particularly vascular in nature as a result of disruption of the VHL gene and/or its upstream pathway leading to upregulation of the hypoxia-inducible factor transcription factor. The hypoxia-inducible factor pathway drives angiogenesis by upregulating VEGF and bFGF, amongst other proangiogenic downstream target genes. Therapies which target angiogenesis have been successful in treating metastatic RCC (mRCC) and the receptor tyrosine kinase inhibitor, pazopanib, is licensed for first line treatment of mRCC. This review details the past, current and future roles of pazopanib in the treatment of mRCC.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available